Latest News
Coya Therapeutics plans open-label extension of COYA 302 ALS trial
14 October 2026 - Biotechnology company Coya Therapeutics Inc (NASDAQ: COYA) announced on Wednesday that it plans to initiate an open-label extension of its Phase 2/3 ALSTARS trial evaluating COYA 302 in amyotrophic lateral sclerosis (ALS), following...
Takeda reports positive Phase 2/3 results for investigational immunodeficiency therapy
14 October 2026 - Healthcare company Takeda (TSE: 4502) (NYSE: TAK) on Wednesday reported detailed results from its pivotal Phase 2/3 IgGNITE trial of investigational TAK-881 for primary immunodeficiency disease (PID), demonstrating comparable pharma...
Galderma to acquire ZO Skin Health for USD1.5bn to expand skincare portfolio
14 October 2026 - Dermatology company Galderma (SIX:GALD) announced on Wednesday that it has agreed to acquire 100% of ZO Skin Health, a physician-dispensed skincare brand, for an enterprise value of USD1.5bn in an all-cash transaction.Founded by der...
Orexo reports encouraging initial bioavailability results for oral semaglutide formulation
14 October 2026 - Swedish pharmaceutical company Orexo AB (STO:ORX) (OTCQX:ORXOY) on Wednesday reported encouraging results from its first preclinical in vivo pharmacokinetic study of an oral semaglutide tablet developed using its proprietary AmorphO...
Pharming reports positive Phase II results for leniolisib in genetic immune disorders
14 October 2026 - Biopharmaceutical company Pharming Group N.V. (Euronext Amsterdam:PHARM) (NASDAQ:PHAR) on Wednesday reported positive topline Phase II trial results for leniolisib in genetically identifiable primary immunodeficiencies (PIDs) with i...